Clinical research suggests that combining a novel agent called navtemadlin with DNA-damaging chemotherapy for the treatment of glioblastoma, a form of brain cancer, could increase efficacy.

Historically, clinical trials have under-represented women and minorities. Clinical Trial Media's Cara Brant offers ...

Elisa Cascade, CPO at Advarra explains why addressing the challenges faced by clinical research sites is vital for improving ...

Friends and family of a much-loved health advocate gathered to celebrate the naming of a new room in his name.